Repair Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Repair Inc.
Angioblast begins US stem cell trial for heart failure
Angioblast Systems has begun what it says is the first clinical trial with allogeneic stem cells for the treatment of serious heart failure.
Ikaria licenses cardiac therapy from BioLineRx
Ikaria has obtained a worldwide exclusive licence to BioLineRx’s BL-1040, a potential treatment for preventing cardiac damage following a heart attack, for up to $282.5 million.
Cdn$94 million boost for genomics research in Ontario
Genomics research in Canada has received a Cdn$94 million ($51.5 million) boost from the Ontario government to support continued research in the area.
First advanced therapy, ChondroCelect, OKd in EU for knee damage
A cell-based medicine for repairing knee damage has become the first product to be recommended for approval by the European Medicines Agency under the EU's new advanced therapy regulatory framework.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice